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Abstract.  The paired helical filaments (PHFs) of Alz- 
heimer's disease were purified by a  strategy in which 
the neurons and amyloid plaque cores of protein 
(APCP) were initially isolated. This was achieved by 
several steps of isocratic sucrose centrifugations of in- 
creasing molarity and a discontinuous isotonic Percoll 
density gradient. After collagenase elimination of con- 
taminating blood vessels,  lysis of neurons was pro- 
duced by SDS treatment. The released PHF cytoskele- 
tons were separated from contaminating APCP and 
lipofuscin by sucrose density gradient.  A  final step 
consisted in the chemical purification of highly en- 
riched PHFs and APCP components via a  formic acid 
to guanidine hydrochloride transition.  PHFs and 
APCPs were fractionated by size exclusion HPLC 
and further characterized and quantitated by automatic 
amino acid analysis. We also present some of the mor- 
phological and immunochemical characteristics of 
PHF polypeptides and APCP. Our studies indicate that 
apart from differences in localization and morphology, 
PHF and APCP significantly differ in (a) chemical 
structure (peptide and amino acid composition); (b) 
epitope specificity (antiubiquitin, antitau, antineurofila- 
ment); (c) physicochemical properties (structural con- 
formation in guanidine hydrochloride); and (d) 
thioflavine T  fluorescence emission. These parameters 
strongly suggest important differences in the composi- 
tion and, probably, in the etiopathology of PHF and 
APCP of Alzheimer's disease. 
ZHEIMER'S disease (AD) ~ is a primary degenerative 
dementia characterized by a progressive  loss of mem- 
ory, perception, orientation, reasoning, and judgement 
that escalates with time until all the intellectual and social 
functions of the individual are lost (61, 65,  68).  Two out- 
standing histopathological lesions found mainly in the cere- 
bral cortex of the Alzheimer degeneration are the neuritic 
(senile) plaques and the intracellular neurofibrillary tangles 
(NFTs) (30, 31, 62, 63). Neuritic plaques are a collection of 
dystrophic neurites surrounding an extracellular deposition 
of filamentous structures, known as the amyloid plaque core 
protein (APCP), whose major component has been recently 
isolated and characterized (13, 36, 37). Apparently these fila- 
ments are produced by the polymerization of a short poly- 
peptide chain (the I~-amyloid protein), derived from the pro- 
1.  Abbreviations  used  in  this  paper:  AD,  Alzheimer's  disease;  APCP, 
amyloid plaque core protein; DAB-S, disaggregation buffer containing 10 
mM Tris-HCl, pH 7.4, 0.25 M sucrose, 2 mM EDTA, 200 mg/ml PMSF, 
500 I.tg leupeptin, 700 p,g/ml pepstatin, 50 mg/liter Gentamicin sulfate, and 
250 ~tg/liter Amphotericin-B; MAP, microtubule-associated protein; NFT, 
neurofibrillary tangles (light microscopic description); PHF, paired helical 
filament (electron microscopic appearance); TBS, Tris-buffered saline (10 
mM Tris-HCl,  pH 7.4, 0.15 M  NaCI,  and 0.02%  Tween-10). 
cessing of a much larger precursor (28, 33, 49, 60), which 
resembles a cell surface receptor and whose mRNA is ex- 
pressed in neuronal cells (3, 9, 14, 21, 73). The gene respon- 
sible for this putative receptor has been mapped to human 
chromosome 21  (15, 50,  58).  However,  the cells that ulti- 
mately produce these anomalous extracellular amyloid fila- 
ments have not been unequivocally identified (36, 42, 52, 62, 
63, 67, 69-71). Neurofibrillary tangles represent an intracyto- 
plasmic collection of paired helical filaments (PHFs), made 
of two helically intertwined 10-nm-diam filaments, with a 
70-nm periodicity (30, 31, 62, 63).  The origin and precise 
chemical nature of these filaments are still a highly debated 
issue (1,  12). 
Even  though NFTs  and neuritic plaques  are  the major 
histopathological lesions of AD, they are not restricted only 
to this disease. Tangles are formed in brains of people with 
several other neurological disorders including the Parkinson 
dementia complex of Guam, Down syndrome, and as the re- 
sult of trauma in the aftermath of boxing (11, 22).  Further- 
more, tangles and plaques also appear to be components of 
the brain of normal elderly individuals (64).  However,  be- 
cause of the extensive damage that these lesions cause to the 
central nervous system, tangles and plaques may play an im- 
portant role in the dementing process of AD. 
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seem to suggest a genetic origin for this type of AD (57). 
Using restriction fragment length polymorphisms and link- 
age analysis, the primary genetic defect in these individuals 
was localized a few centimorgans away from the 13-amyloid 
locus in chromosome 21 (59, 66). This suggests that, while 
the I~-amyloid protein is important for the disease state,  it is 
not the primary defect at least in this form of familial AD. 
In addition, it has not been shown that either familial AD or 
sporadic AD (the latter representing the majority of the AD 
cases) is caused by the same genetic defect. 
It has been reported by some investigators that PHFs of AD 
are chemically identical to the extracellular 13-amyloid pro- 
tein of the neuritic plaque (36). This has become a contro- 
versial issue since PHFs seem to carry epitopes shared by 
normal cytoskeletal components, like the microtubule-asso- 
ciated proteins MAP (34, 47), tau (18, 35, 44, 56, 72), and 
neurofilaments (2,  10, 39, 41, 47), as well as the proteolytic 
signal protein ubiquitin (43, 48, 56), all of which apparently 
are not found in the I~-amyloid protein. To compound the is- 
sue  further,  during  the  isolation process,  preparations  of 
PHF tend to be contaminated to a variable degree by fila- 
ments from the 13-amyloid protein of the neuritic plaque, as 
well as by other insoluble components (1, 54). 
It appears that PHFs substitute for the normal cytoskeletal 
elements in the affected neurons, mainly microtubules and 
neurofilaments (16), and affect the shape or form of the cell. 
Because of their insolubility and increasing accumulation, 
PHFs become a very important structural component of the 
cytoarchitecture of AD  neurons.  Furthermore,  even after 
cellular death these elements remain as neuronal "fossils" or 
cell "ghosts" (54). Moreover, as mentioned above, PHFs have 
been shown to carry epitopes of normal cytoskeletal compo- 
nents.  For the sake of clarity of definition and to describe 
more accurately the probable, although anomalous, function 
of the PHF, we use the term PHF cytoskeletons. 
In this paper, we describe a technique for the isolation of 
neurons from frozen brain tissue.  This method eliminates 
glial cells and blood vessels and leads to the ultimate puri- 
fication of the pathological PHF cytoskeletons and APCP. In 
addition,  we present biochemical data which indicate that 
the composition ofPHF cytoskeletons differs from those pre- 
viously published,  and more importantly, from the APCP. 
Following this scheme of purification, PHF cytoskeletons re- 
tained epitopes for normal cytoskeletal elements and ubiq- 
uitin.  Moreover, after depolymerization of PHF cytoskele- 
tons and APCP by formic acid, followed by removal of this 
denaturing agent, the PHF cytoskeletons failed to reassemble 
into their native configuration. By contrast, APCP repoly- 
merized into homogeneous 10-nm filaments. 
Materials and Methods 
Isolation of  Neuronal Cells 
Brains from eight patients who died as the result of AD were obtained within 
an average period of 8 h postmortem. The right cerebral hemispheres were 
immediately frozen and stored at  -70°C until the moment of use. The left 
cerebral hemispheres were histologically processed for diagnostic and mor- 
phometric studies. The clinical diagnosis of primary degenerative dementia 
of Alzheimer type was confirmed in every instance not only by routine neu- 
ropathologic examination but also by accepted quantitative criteria.  Each 
case met the diagnostic criteria for neuritic plaques and neurofibrillary tan- 
gles recommended by the National  Institutes of Health Neuropathology 
Panel  (29).  Additionally, each  case fulfilled the rigorous morphometric 
criteria published from the Dementia Study Laboratory, University of West- 
ern Ontario (4, 5). A sample of the dramatic histopathologic severity of le- 
sions in these eight hemispheres is provided in Table I.  The eight hemi- 
spheres used in the present study, were removed from the -70°C freezer 
(Revco Inc., West Columbia, SC) and allowed to thaw to 'x,15°C.  Coronal 
sections (0.5 cm thick) were made and immediately immersed in the dis- 
aggregation buffer (DAB-S) at 4°C, containing 10 mM Tris (hydroxymethyl) 
aminomethane (Tris)-HCI,  pH 7.4,  0.25  M  sucrose, 2  mM EDTA,  200 
mg/liter  PMSE  500  p.g/liter  leupeptin,  700  I.tg/liter  pepstatin,  50  mg/ 
liter Gentamicin sulfate, and 250 ~g/liter Amphotericin B. After dissection 
of the unwanted white matter, leptomeninges, and large blood vessels from 
the coronal sections, the cortical grey matter, including hippocampus and 
amygdaloid nucleus (total  yield, 2,000 g) was finely minced with a  razor 
blade, mixed with 6 vol DAB-S and vigorously stirred with a magnetic bar 
overnight. The tissue suspension was then successively filtered through a 
series of stainless steel meshes of 1.4 mm, and 700, 300, and 150 p.m. The 
filtered material was centrifuged at 8,000 g  for 15 min using a JA-14 rotor 
(Beckman Instruments, Inc., Palo Alto, CA).  The resulting pellets were 
resuspended in DAB-S to which solid sucrose was added to yield a final su- 
crose concentration of 0.8 M  and centrifuged at 8,000 g  for 30 min. The 
pellets were again resuspended in DAB-S and adjusted to 1.3 M sucrose con 
centration, filtered through a  150-I.tm mesh and centrifuged at 15,000 g for 
30 rain.  The dense layer floating at the top of the centrifuge bottles was 
vacuum aspirated. The pellets at the bottom of the bottles were resuspended 
in  DAB-S at a  final concentration of  1.9  M  sucrose and centrifuged at 
50,000 g for 30 min using an SW-28 rotor (Beckman Instruments, Inc.). The 
compact top layer was removed with a  spatula. This material was resus- 
pended in DAB-S, in which the 0.25 M sucrose was substituted by 0.15 M 
NaCI (DAB-NaCI), and submitted to a discontinuous NaCl-isotonic Percoll 
(Percoll 400) density gradient centrifugation (700 g for 30 min, at 20°C). 
The gradient was formed by 10 ml each of 44, 34, 27, and 20% Percoll con- 
centrations. The fractions contained at the 44/34, 34/27, and 27/20% inter- 
faces were washed four times with 50 mM Tris-HCl, pH 8.0, 2 mM CaCI2 
at 1,500 g for 10 min, resuspended in the same buffer to which 0.2 mg/ml 
of collagenase (CLS III;  Worthington Biochemical Corp.,  Freehold,  NJ) 
and 10 l~g/ml of DNase I (Calbiochem-Behring Corp., San Diego, CA) were 
added,  and incubated at  37°C for  14 h.  Removal of enzymes and their 
byproducts and  recovery  of neurons was achieved by  repetitive  washes 
(1,500 g,  15 min) with 0.15 M  NaCI. 
Preparation and Purification of Paired 
Helical Filaments 
Neurons were resuspended in 4 vol of 0.15 M NaCI followed by the addition 
of 15 vol of 2% SDS, 50 mM Tris-HCl, pH 8.0. Cellular lysis was allowed 
to proceed for 30 min at room temperature with intermittent gentle shak- 
ing.  All  soluble cellular components were  removed by centrifugation at 
1,500 g for 30 min. The brown pellets were washed twice more with 1.5% 
SDS  under the same conditions. The recovered  pellets (from the initial 
Table L Morphometric Features Confirming Diagnosis 
of  Alzheimer's Disease 
Age  Sex 
Morphometric observations" (hippocampal  cortex) 
Adjusted  Adjusted  Neuronal 
tangle  granulovacuolar  density/ 
index/mm  3  index/mm  3  mm  3 
63  F  159.8  317.1  3,500 
78  M  27.9  403.4  3,898 
74  M  168.1  452.1  5,857~ 
77  F  93.3  292.1  2,548 
76  M  136.1  426  5,551 
84  M  80.2  251  5,185 
69  M  i 13.6  223.5  3,806 
74  M  101.8  322. t  4,995 
* Of these 24 parameters quantified in the eight cases, 23 exceed the mini 
mum severity  required  (tangles  >20/mm3;  granulovacuoles  >55/mm~;  neurons 
<5,600/mm3). 
In one case, two of the three lesions exceed the minimum, but only one of 
three need do so to confirm the diagnosis (4). 
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granules, and a  small amount of unidentified insoluble cell debris. These 
pellets were resuspended in 50 ml of 1.5%  SDS and submitted to a discon- 
tinuous sucrose density gradient prepared in 50 mM Tris-HCl, pH 8.0, 1.5 % 
SDS and formed by 2  ml each of 2.1, 2.0,  1.7, 1.4 M  sucrose and 1.5 ml 
each of 1.3 and  1.2 M  sucrose, respectively. A total of 48 gradient tubes 
(14  ×  89  mm) were  prepared.  A  1-ml aliquot of the above SDS-insol- 
uble material was loaded at the top of each of the tubes and centrifuged at 
200,000 g for I h at 20°C in an SW 41 Ti rotor (Beckman Instruments, Inc.). 
The resulting interfaces were aspirated with a peristaltic pump and the su- 
crose removed by dilution and three washes with 0.5 % SDS in 25 mM Tris- 
HCI, pH 8.0. The 2.1/2.0-M interface contained more than 90% pure PHF 
cytoskeletons; the remaining 10%  consisted of lipofuscin granules and a 
negligible amount of APCP. The 2.0/1.7-M  interface was composed of 80% 
PHF cytoskeletons. The 1.7/1.4-M  interface, on the other hand, contained 
80 % APCP, 20 % PHF cytoskeletons (of smaller size and sparer concentra- 
tion)  and lipofuscin granules. The  1.3/1.4-M  interface was composed of 
APCP and lipofuscin. 
Since the largest quantity of PHF cytoskeletons localized at the 2.0/1.7-M 
sucrose interface,  we  further enriched these structures by  resuspending 
them in 1.0 M  sucrose, 0.5% SDS, followed by centrifugation at 200 g for 
15 min in conical 1.5-ml reactive vials. A small brown pellet, mainly lipo- 
fuscin plus some PHF cytoskeletons and some large APCP aggregates, col- 
lected at the bottom of the vial. The supernatant was recentrifuged at 600 g 
for 15 min, yielding a small brown pellet. The pellet was discarded and a 
large pale brown intermediate layer plus a whitish turbid supernatant were 
subsequently recovered by centrifugation at 1,500 g. These latter two frac- 
tions contain more than 95%  PHF cytoskeletons, which differed only in 
their sizes and degree of filament aggregation. 
Further purification of the PHF proteins was obtained by dissolving a pel- 
let of 150 ~tl of PHF cytoskeletons in 2.2 ml of concentrated (89%) formic 
acid, allowed to stand at room temperature for 20 min, followed by centrifu- 
gation at 1,500 g for 10 min. The supernatant was collected and centrifuged 
at  12,000 g  for a  further  10 min. The two centrifugations permitted the 
elimination of a  small amount of remaining lipofuscin granules, mainly 
those entrapped in the network of PHF cytoskeletons. The supernatant con- 
taining the solubilized PHF proteins was then dialyzed (dialysis tubing cut 
off 1,0(30 D) against two changes (500 ml each) of 6  M  guanidine-hydro- 
chloride (GHCI),  125  mM Tris-HCl, pH 8.0, 5 mM DTT. When the first 
dialysis buffer reached a pH of 4.0 ("~4 h), the dialysis bag was transferred 
to the second vessel whose pH, overnight, equilibrated at 7.5. The clear con- 
tent of the dialysis bag was then centrifuged in polyallomer tubes at 250,000 g 
for 20 min (TLA 100.2 rotor; Beckman Instruments, Inc.). A minute pellet, 
estimated to be no more than 2  ~tl, was produced. The clear supernatant 
was stored at  -70°C until the moment of use. 
Purification of  APCP 
The materials collected at the 1.7/1.4- and 1.4/1.3-M sucrose gradient ¢en- 
trifugation described above were enriched with APCP. To remove the con- 
taminating lipofuscin, a  sucrose-free aliquot of 900 ktl, pooled from both 
interfaces, was washed three times with  15 ml of distilled water (1,500 g, 
10 rain). The resulting pellet was then thoroughly resuspended in 6 ml of 
89% formic acid and, after standing at room temperature for 20 min, cen- 
trifuged at  1,500 g  for 15 min. Most of the lipofuscin granules were col- 
lected at the bottom of the tube. The pale yellow supernatant was centrifuged 
once again at 12,500 g for 10 min. The resulting clear supernal,ant was dia- 
lyzed against 6 M GHCI in the same manner as described for the purifica- 
tion of PHF protein but excluding the DTT. When the pH of the dialysis 
buffer reached 3.0, a white flocculent precipitate formed in the bag. After 
a second change of the dialysis buffer (pH 7.5), the precipitated material was 
recovered by centrifugation at 12,500 g for 10 min. The pellet, which had 
a semitransparent  jellylike consistency, contained the repolymerized 10-nm 
filaments of the APCP. This material was washed twice with dialysis buffer 
and stored at 4°C. 
Morphological Analysis 
All experimental steps involved in neuronal isolation, preparation of PHF 
cytoskeletons, and APCP purification were monitored by phase and fluores- 
cence microscopy, as well as by transmission electron microscopy. A rapid 
technique which permitted the detailed analysis of neuronal integrity was 
achieved by staining the cells with either the carbocyanine D272 (3,3'-dipen- 
tyloxocarbocyanine iodide) or the carbocyanine D378 (3,3'-diheptyloxocar- 
bocyanine iodide)  obtained from Molecular Probes,  Inc.  (Junction City, 
OR). An aliquot of the cell suspension to be morphologically assessed was 
washed with 0.15  M  NaCI,  10 mM Tris-HCl, pH 7.4 and resuspended in 
10 vol of the same buffer.  10 lal of cell suspension was spread on a slide, 
allowed to dry in an oven at 37°C for 15 min and fixed in absolute ethanol 
for  15 min. After rinsing with distilled water, the slides were stained for 
2-3 min with a 25-p.g/ml solution of carbocyanine (stock solution, 1 mg/ml 
ethanol), prepared in 10 mM Tris-HC1, pH 7.4, and, just before use, acidi- 
fied with HC1 to a concentration of 0.05%. The slides were then rinsed in 
distilled water, mounted in Bacto FA fluid (Difco Laboratories Inc., Detroit, 
MI) and observed in an Axiophot epifluorescence microscope (Carl Zeiss, 
Inc., Thornwood, NY), equipped with an excitation filter (450-490 nm) and 
a barrier filter (520 nm). 
The presence of PHF cytoskeletons and APCP was monitored by thio- 
flavine T staining. We chose this fluorochrome because under acidic condi- 
tions it permitted a clear distinction between these two flamentous struc- 
tures. When excited at 350 nm, PHF cytoskeletons stained bright green and 
APCP a  silver or deep blue. A  drop of the specimen to be assessed was 
spread on a  slide, air dried,  and fixed in absolute ethanol for  1 h. Thio- 
flavine T (250 mg) was dissolved in 5 ml of absolute ethanol, and the vol- 
ume made up to 50 ml with 50 mM Tris-HCl, pH 8.0. To acidify the solu- 
tion, 400 lal of concentrated HCI was added before use. The fixed specimens 
were rinsed with water and stained for 10 min. After rinsing away the excess 
fluorochrome with water,  the slides were mounted using Bacto FA fluid 
(Difco Laboratories, Inc.) and observed in a fluorescence microscope (exci- 
tation  filter,  370  nm).  When necessary, the quantity and  quality  of the 
purified PHF cytoskeletons and APCP preparations were determined by 
transmission electron microscopy, using Formvar-coated grids stained for 
4  min with 1% aqueous uranyl acetate and observed on a  100 CX micro- 
scope (JEOL USA, Electron Optics Div., Peabody, MA) at 60 kV. 
Light Microscopic Immunocytochemistry 
Purity of Neuronal Preparation. Determination of the glial contamination 
in our neuronal preparations was made by immunocytochemistry using a 
monoclonal antibody against galactocerebroside and polyclonal antibodies 
against myelin basic protein and glial fibrillary acidic protein.  A cell sus- 
pension (100  ~tl) was washed with 10 mM PBS (Na2  HPO4, pH 7.2, 0.15 
M NaCI)and resuspended in 100 ~tt of 4% paraformaldehyde. After 15 min 
at room temperature the cells were washed three times with PBS and in- 
cubated with 200 lal of either normal mouse or rabbit serum (1:20 dilution) 
containing 3% BSA. This was followed by three washes with PBS and the 
addition of the above-mentioned antibodies diluted 1:50 in PBS. After a l-h 
incubation, the specimens were washed three times with PBS, 200 lal of 
FITC-labeled goat anti-mouse or goat anti-rabbit serum (1:100  dilution) 
was added accordingly, incubated 45 rain at room temperature, washed three 
times with PBS, and mounted with a drop of Bacto FA fluid (Difco Labora- 
tories, Inc.). 
PHF Preparations.  Diluted aliquots of PHF  cytoskeletons recovered 
from the final centrifugation steps were spread on clean glass slides and 
dried at 37°C for 1 h. The slides were washed twice with PBS and incubated 
with normal goat serum (diluted  1:5 with PBS) for 5 min. After three 15- 
min washes with PBS,  the slides were incubated with primary antibody 
(1:100 for antiubiquitin and antitau; 1:50 for antineurofilament) for 30 min 
at room temperature. Slides were again washed three times with PBS and 
incubated with the second antibody conjugated to FITC (goat anti-rabbit 
IgG for ubiquitin and tau or goat anti-mouse IgG for neurofilament pro- 
tein-all diluted 1:50)  for 30 min at room temperature. After incubation, 
the slides received three washes with buffer, gently blotted and mounted in 
Bacto FA medium (Difco Laboratories, Inc.) for fluorescence microscopy. 
In  an  additional  series  of experiments,  PHF  preparations  were  double 
stained with rhodamine- and fluorescein-labeled second antibody (TRITC- 
goat anti-rabbit  IgG against tau and FITC-goat anti-mouse IgG against 
neurofilament) using the same protocol as above. 
lmmunostaining of  PHF  Proteins 
Immunoreactivity of PHF proteins was assessed by immunostaining on a 
dot blot as follows: 2-I.tl aliquots of the proteins to be investigated were spot- 
ted directly onto nitrocellulose filters (BA85; Schleicher &  Schuell, Inc., 
Keene, NH) and washed twice with 20 ml of Tris-buffered saline (10 mM 
Tris-HC1, pH 7.4, containing 0.15 M  NaCI and 0.02% Tween-10; TBS) to 
remove any residual GHC1. The filters were then blocked with a solution 
containing 2% ovalbumin in TBS for I h. Proteins bound on the filters were 
assayed for their immunoreactivity to antibodies directed against ubiquitin, 
tau, and neurofilament proteins with secondary antibodies conjugated with 
Roher et al. Paired Helical Filaments of Alzheimer's Disease  2705 alkaline phosphatase (7).  Antibodies directed against ubiquitin were raised 
in rabbits with ubiquitin conjugated to keyhole limpet hemocyanin (20), as 
has been described by Meyer et al. (38). Antibody against tau was obtained 
from ICN Biomedicals, Inc. (Costa Mesa, CA) and that against neurofila- 
ment (8D8) was a generous gift from Dr. Brian Anderton, St. George's Hos- 
pital, London, England. 
Amino Acid Analysis 
Amino acid analysis of proteins was carried out in 6 M  HCI, containing 
1.0% phenol, in melting point tubes at 108°C for 24, 48, and 72 h. Alterna- 
tively, hydrolysis was performed at 150°C for 75 min on a PicoTag worksta- 
tion (Waters Instruments, Inc., Rochester, MN). After removal of the acid 
in a SlW.edvac  centrifuge, the specimens were derivatized to form phenyl- 
thiocarbamyl amino acids and  separated by HPLC  on a  Novapack CI8 
column (Waters  PicoTag;  Waters  Instruments, Inc.). 
HPLC 
300-!al aliquots of  the PHF peptides, soluble in 6 M GHCI, were centrifuged 
at 250,000 g for 20 min (TL 100.2 rotor, Beckman Instruments, Inc., Palo 
Alto, CA) and submitted to size exclusion chromatography on a TSK 3000 
SW column (600  x  7.5 mm; Beckman Instruments, Inc., Altex Division, 
San Ramon, CA) with a mobile phase of 6 M GHCI containing 5 % formic 
acid. 
The material precipitating in 6 M GHC1, containing the APCP peptides, 
was separated from the soluble PHF in the supernatant by centrifugation. 
The resulting pellet was twice washed with 6 M GHC1, resolubilized by the 
addition of 8 vol of 88%  formic acid and dialyzed (membrane cut off of 
1,000 D) against four changes (500 ml each) of 70%  formic acid for 4 h 
at 2°C. The optically transparent specimen was centrifuged at 250,000 g for 
20 min at 4°C. Aliquots of 300 ~tl were chromatographed on a  Superose 
12 size exclusion column (300 ×  10 mm; Pharmacia Fine Chemicals, Pis- 
cataway, NJ) using as mobile phase 70%  formic acid. 
Results 
The purification scheme used in the present investigation is 
succinctly summarized in Fig.  1. We found that,  in spite of 
having remained frozen at  -70°C for an average period of 
60 mo, the AD brain tissue used in this study yielded neu- 
rons which, morphologically, did not differ from those iso- 
lated in our laboratory from fresh tissue processed immedi- 
ately postmortem. We believe that an important step in the 
conservation of cell morphology was the sectioning and ini- 
tial processing of the brain cortex in isotonic sucrose while 
still frozen. In addition, the incorporation of enzyme inhibi- 
tors in the freshly made disaggregation buffers helped to pre- 
vent undesirable proteolysis of cells. Gentle filtration of the 
brain tissue through a series of decreasing aperture stainless 
steel meshes, instead of the use of nozzle aspiration or sy- 
ringe pressure forcing, minimized the unavoidable mechani- 
cal trauma to the cells. An example of the quality of preserva- 
tion of the neurons obtained up to this point is illustrated in 
Fig.  2.  A  series of preliminary studies established that the 
best routine  for the  enrichment of the cellular population 
consisted of the bulk elimination of myelin and cell debris, 
derived from the mincing of the tissue and subsequent filtra- 
tion,  by centrifugation  in  0.8  M  sucrose.  These materials 
floated at the top of the centrifuge bottle or loosely accumu- 
lated at the surface of the bottom pellet and were eliminated 
by careful and fast decantation. Increasing the sucrose con- 
centration to 1.3 M, followed by centrifugation, resulted in 
the formation of a large aggregation of material at the top of 
the bottle. Because of its compact consistency, this material 
was removed by vacuum aspiration.  Microscopic examina- 
tion showed it to consist of glial cells,  blood vessels, cell 
processes, and other cell debris. When the sucrose concen- 
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Figure 1. A flow chart summarizing the strategy used in our labora- 
tory for the purification of PHFs and APCP of AD. This consisted 
of (a) isolation of neurons and amyloid cores, (b) lysis of cells by 
SDS, (c) separation of PHF cytoskeletons, APCP, and lipofuscin 
via a sucrose gradient, and (d) a final physicochemical purification 
of PHF and APC polypeptides. 
tration was increased to 1.9 M, the enriched neuronal popu- 
lation floated on the surface of the medium as a semisolid 
pellet that was easily scooped out with a spatula, whereas the 
pellet at the bottom of the  tube contained  numerous free 
nuclei.  Percoll  density gradient centrifugation further en- 
riched the neuronal fraction. 
The use of antibodies against the oligodendrocyte antigens 
(myelin basic protein and galactocerebroside) and against the 
astroglial marker (glial fibrillary acidic protein) revealed the 
presence of two glial cells per 3,000 neurons in the 44/34% 
Percoll interface.  The 34/27 and 27/20%  Percoll interfaces 
contained 2 and 10% glial cells, respectively. The materials 
retained at the top of the gradient (20 % Percoll and above) 
and at the bottom of the tube were discarded. However, small 
blood vessel fragments of various sizes still contaminated the 
enriched neuronal interfaces. Since our objective was to fur- 
ther concentrate the neuronal population containing the PHFs 
of AD,  we decided to use collagenase.  This enzyme com- 
pletely eliminated the remaining blood vessels. Unfortunately, 
a number of the neuronal processes were detached from their 
The Journal  of Cell Biology,  Volume 107, 1988  2706 Figure 2.  Neurons isolated from frozen brain tissue by the tech- 
nique outlined in Materials and Methods during the early prepara- 
tive stages before collagenase digestion. Neurons in the top and bot- 
tom panels were stained with carbocyanine D272, and those in the 
middle panels with the carbocyanine  D378. These cationic lipophilic 
probes have a high quantum yield and a high affinity for membranes 
that produces remarkable detail of the cell membrane and underly- 
ing organelles. In addition, the very fine resolution of these fluoro- 
chromes  atso permits the  identification and visualization of the 
detailed morphology of neurites, including varicosities and append- 
ages. Bar, 60 lam. 
respective cells during the digestion.  Additionally, a  small 
proportion  of cells  was  also  destroyed.  Release  of DNA 
caused some clumping, a phenomenon avoided by the use of 
DNase I. At all experimental steps in this study we estimated 
the quality and composition of our preparations by carbo- 
cyanine staining. This technique, outlined in Materials and 
Methods, permits a very rapid and refined assessment of the 
cellular structures, as shown in Fig. 2. No major staining dif- 
ferences were found between the two carbocyanines used in 
this study. 
Complete disintegration and solubilization of cellular struc- 
tures was achieved by the use of SDS.  After washing away 
the soluble fraction, the only remaining insoluble materials 
were PHF cytoskeletons, lipofuscin granules,  and a  small 
amount of insoluble cell debris. Mixed with these insoluble 
structures were the APCP. Because of their insolubility, size, 
and  density,  these  proteins  copurified  with  the  neuronal 
population  during  the  course  of their  isolation.  A  final 
purification step using sucrose density gradient centrifuga- 
tion yielded a  series of discrete bands of highly enriched 
PHF cytoskeletons and amyloid cores, whose composition 
was described in Materials and Methods. As can be seen in 
Figs. 3-5, most of the PHF cytoskeletons still retained their 
cellular  shape  and,  in  some  cases,  surrounded  a  central 
"cavity" which was previously occupied by the nerve cell nu- 
cleus. The only contaminant in our best preparations con- 
sisted of a  small  amount of lipofuscin granules entrapped 
within the PHF cytoskeletal network (Fig. 4). Those inter- 
faces rich in amyloid cores were very homogenous also, as 
illustrated in Fig.  6. 
Immunofluorescence studies using antiubiquitin, antitau, 
and antineurofilament antibodies revealed that each of these 
antigenic epitopes was present on the purified PHF cytoskel- 
etons, as shown in Fig. 7. Moreover, we questioned whether 
these antigens, specifically tau and neurofilament, were car- 
ried by all PHFs simultaneously. Dual labeling immunofluo- 
rescence studies  using  FITC- and TRITC-coupled second 
antibody indicated that there were heterogeneous populations 
of PHF in terms of the presence of tau and neurofilament 
proteins.  Although a  majority of PHFs demonstrated dual 
fluorescence, clearly many PHFs were only weakly positive 
or entirely negative for one or both antigens. Similar obser- 
vations have been reported by other investigators in other 
PHF preparations (17, 56). 
The total amino acid composition of our best PHF prepa- 
rations, which we conservatively estimated to be 95 % pure, 
is given in Table II. The composition differed substantially 
(P =  0.002) from those published for the APCP, both by our- 
selves (51) and by others (36,  54).  Glycine, glutamic acid, 
and  lysine appeared to be the three most abundant amino 
acids. 
The highly enriched PHF cytoskeletal and APCP fractions 
were purified further by solubilization in concentrated for- 
mic acid, followed by dialysis against 6 M GHC1. We found 
that, even in the presence of the latter denaturing agent, the 
APCP components repolymerized into variable length filamen- 
tous structures measuring 10 nm in diameter which formed 
aggregates very similar to those observed before depolymer- 
ization (Fig. 8). In addition, the repolymerized APCP was 
negative for ubiquitin,  tau,  and neurofilament antigens,  as 
they also were in situ and before depolymerization. Further- 
more, the amino acid composition of this fraction (Table II) 
highly resembled that previously obtained in our laboratory 
for the APCP, when these structures were purified by fluo- 
rescence-activated cell sorting (51). 
In contrast, the components of the PHF cytoskeletons re- 
mained soluble during the transition from formic acid to 6 M 
GHC1. An aliquot of this material was directly tested for the 
presence of ubiquitin, tau, and neurofilament epitopes. All 
three antigens were present in this fraction by dot blot assay. 
Attempts to repolymerize  the PHF by removing the GHCI by 
dialysis against either 0.5 % ammonium bicarbonate or 1.5 % 
formic acid failed to recreate the native characteristics of the 
bi-filar, intertwined (helical) structure of the PHFs. Instead, 
we observed aggregates of  protein which showed, at their pe- 
riphery, both short, reticularlike structures and a more con- 
densed heterogeneous filamentous component. 
Size exclusion chromatography of the formic acid/6 M 
GHCl-solubilized PHF peptides yielded five discrete peaks 
(Fig. 9 A). The Mr of fractions 1-3 were 200,000,  9,000, and 
4,500, respectively. Fractions 4 and 5 had a longer retention 
time than the neurotensin marker (Mr 1,700) and therefore 
their Mr could not be assigned.  The amino acid composi- 
Roher et al. Paired Helical Filaments of Alzheimer's Disease  2707 Figure 3. Thioflavine T-stained PHF cytoskeletons obtained from 2.1/2.0-M sucrose interface shown in Fig. 3. This layer contained more 
than 90% PHF cytoskeleton (assessed by fluorescence and electron microscopy). A small amount of lipofuscin granules (arrows)  and some 
small specks of APCP (arrowhead)  still contaminated the specimen. Acid thioflavine T staining was chosen (over thioflavine S or Congo 
red) because when the specimens were excited at 370 nm, the APCP fluoresced in blue (emission, 420 nm), and the PHF cytoskeletons 
in green-yellow (emission, 520 nm). The autofluorescence of lipofuscin was also differentiated (emission, 450 nm). Hence, besides their 
morphology, all those structures were clearly distinguished by fluorescence microscopy. Bar, 20 gm. 
tions of these polypeptides are given in Table III. Fractions 
2 and 3 appear to be highly related in composition and Mr, 
suggesting that fraction 2 may be a dimer of fraction 3. These 
molecules are rich in Gly, Glu, Ser, and Asp. Although frac- 
tions  1 and 4  also resemble one another, having Glu, Gly, 
Asp, and Ser as their more abundant amino acids, neverthe- 
less, important differences must exist between these two pro- 
teins. Fraction I is the only one in the entire set which proved 
positive for ubiquitin, tau, and neurofilament by immunodot 
blot technique. Amino acid analysis also permitted the direct 
calculation of the molar ratio among the five components. 
Fraction 4 appears to contain most of the protein (64%) fol- 
lowed by fraction 1 (18 %). 
Size exclusion chromatography of formic acid/6 M GHC1/ 
formic acid-solubilized APCP peptides also rendered five 
major fractions (Fig. 9 B) with an apparent Mr of 200,000, 
33,000,  10,000, 5,000,  and an undetermined Mr for peak 5. 
The amino acid compositions of fractions 3 and 4 revealed 
a  close relationship, which suggested fraction 3 was a dimer 
of fraction 4  (Table IV). Furthermore, it is fraction 4 (rep- 
resenting 57 % of the total APCP) that appears to correspond 
to the sequenced 42-amino acid peptide of the 13-amyloid 
(13, 36, 37).  By contrast, fractions 1 and 2 (representing 15 
and 4%, respectively) resembled one another more closely 
than they did either fraction 3 or 4. Among others, the most 
striking differences are in the values of Thr, Pro, Val, and 
Arg. In addition, the peptides obtained from the APCP size 
exclusion chromatography were negative when stained with 
antibodies to ubiquitin, tau, and neurofilament by immuno- 
dot blot. 
Discussion 
In a recent review entitled ~lzheimer's Disease: Its Proteins 
and Genes," Glenner (12) stressed that in spite of the fact that 
the PHFs of this degenerative disease have been the subject 
of intense investigation for over 15 years, their chemical na- 
ture still "remains ill defined: Until now, two principle rea- 
sons have precluded a more definitive advance in this area: 
(a) the inability to obtain appropriately pure specimens of 
PHF  in  quantities  adequate  to  allow  further biochemical 
characterization, and (b) the problem of PHF insolubility. In 
this paper we have presented a protocol which described the 
isolation of neuronal PHF of very high purity and in suffi- 
cient quantity to permit further biochemical characteriza- 
tion. Such studies will help to determine the intrinsic compo- 
sition of these structures. 
With the exception of Iqbal et al.  (25) who,  in  1974,  at- 
tempted to purify PHF from isolated neurons, previous meth- 
odologies (26, 27, 36, 37, 53, 54) aimed at obtaining purified 
PHF fractions used, among others, early homogenization of 
the brain by detergents in the presence of reducing agents 
and, in some cases, the use of proteolytic enzymes or even 
high  temperature treatment.  We  devised a  technique that 
avoided these potentially detrimental procedures (6, 23, 45). 
The preservation of intact neurons up to the final Percoll 
The Journal of Cell Biology,  Volume 107, 1988  2708 Figure 4. Electron micrographs showing a series of PHF cytoskeletons.  (A-F) PHF cytoskeletons obtained from the 2.0/1.7-M sucrose inter- 
face,  which were further purified  by low speed centrifugation  in  1 M sucrose,  as described in the text.  (G-l) PHF cytoskeletons  from 
the 2.1/2.0-M  sucrose interface.  Notice the larger and more compact network of the latter. The cytoskeletons  still preserve what appeared 
to be their previous cellular (body) shape.  In some instances  a central  "cavity" is distinguished  (see also Figs.  3 and 5) that was probably 
occupied by the former nucleus of the intact cell.  In some other cases, elongated  appendages  of PHF depart from a larger globular mass 
of PHF, suggesting an apical dendrite  (I). Some small granules of lipofuscin can be seen entrapped  within the PHF network.  Bars, 5 ~tm. 
fractionation helps to avoid initial contamination of PHF by 
extracellular  APCP and other cellular debris. 
In spite of being frozen at  -70°C for five years, cellular 
integrity was well preserved (Fig. 2). Several factors used in 
the present protocol may have contributed to their preserva- 
tion.  Among them was the initial slicing and mincing of the 
brain at low temperature  in an isotonic medium containing 
protease inhibitors,  as well as the very gentle sieving of the 
tissue  through  decreasing  size  stainless  steel  meshes.  Al- 
though the cells were treated with hypertonic sucrose solu- 
tions, they were exposed to these conditions for the minimum 
time  necessary  followed  by  immediate  return  to  isotonic 
medium.  We  recognize,  however,  that  mechanical  trauma 
and the necessary chemical steps,  as well as the inability of 
the cells to regenerate, were an important source of neuronal 
damage during the isolation procedure.  Nevertheless,  from 
an initial 2,000 g of cortex, we recovered 50 ml of cells (set- 
tled at unit gravity), of which 90%  were neurons, from our 
Percoll interfaces and a final volume of '~150 ~tl of purified 
PHF cytoskeletons. 
In a previous series of experiments,  we used the fluores- 
cence-activated cell  sorter  (FACS)  as  the  final  step  in the 
purification of PHF cytoskeletons. FACS purification, as also 
experienced  by other  laboratories  (24,  40),  was only par- 
tially  successful.  When  reacted  under  acidic  conditions, 
thioflavine T distinctly labeled PHF cytoskeletons and APCP, 
while  the  autofluorescent  lipofuscin  remained  unlabeled. 
Separation of these elements occurred in the FACS when ex- 
cited at 370 nm.  To label these  structures,  however,  it was 
necessary to remove the detergent (SDS). This caused a sig- 
nificant aggregation of cores and  tangles,  which  was very 
difficult to dissociate even after the SDS was reincorporated 
in the buffer. We estimated that the maximum purity of PHF 
cytoskeletons attainable through FACS amounted to no more 
than 70%.  By using the technique presented  in this paper, 
the degree of purity in our best PHF preparations was 95 % 
or more.  At EM level,  the 5 %  contamination consisted of 
some  granules  of lipofuscin  entrapped  within  the  isolated 
PHF cytoskeleton network, and a negligible amount of APCP 
in the form of small but very prominent protein aggregates. 
Moreover, electron microscopy of the isolated PHF cytoskel- 
etons showed them to be homogeneously composed of PHF, 
Roher et al. Paired Helical Filaments of Alzheimer's Disease  2709 The Journal of Cell Biology, Volume  107,  1988  2710 Figure 6. Amyloid plaque protein cores stained with thioflavine T. 
These cores were obtained from the 1.7/1.4-M sucrose density gra- 
dient interface. Thioflavine T staining, when excited at 370 nm, dis- 
tinguishes two discrete types of amyloid cores:  intensely glowing 
silver blue (arrowhead)  and deep dark blue (arrow).  We suggest 
that these differences in staining characteristics may be due to small 
chemical  inequality either  in protein composition  or posttransla- 
tional modification (such as glycosylation and phosphorylation).  A 
second possibility is that they simply represent differences in fila- 
ment concentration. However, in a random sample of  cores, like the 
one shown in this figure, a continuous distribution  of fluorescent 
tones is rarely  seen. Bar,  l0 tam. 
as established by filament measurements of 20-24-nm di- 
ameter and 70-nm axial periodicity. 
As the data presented in Table II clearly show, the amino 
acid composition of PHF substantially differed from APCP 
and lipofuscin molecules. The relative amounts of eight amino 
acids (Pro, Thr, Met, Arg, Lys, Phe, Ser, and Ala) differed 
by more than 40%, when the values of PHF and APCP were 
compared.  The most represented amino acids  in the PHF 
were Gly, Glu, Lys, and Asp, while in the APCP they were 
Gly,  Val,  Glu,  and  Ala.  These  results  strongly  suggest a 
different protein composition and quite possibly a different 
pathogenesis as  well.  When  compared to the  PHF amino 
acid compositions published by others (36,  54),  important 
deviations, which could have resulted from different degrees 
of contamination, were apparent. The issue of whether or not 
identity exists between the polypeptide composition of the 
intraneuronal PHFs and the extracellular APCP has not been 
settled.  On the one hand, Masters et al.  (36) and Guiroy et 
al. (19) support the concept of identity based on amino acid 
sequence data between AD-PHF and AD-APCP and between 
the AD-PHF and PHF obtained from patients who died of 
Parkinson dementia complex of Guam. This latter degenera- 
tive  disease  is  purportedly  free  of neuritic  plaques  and, 
therefore, should not contribute a potential APCP contami- 
nation during the isolation procedures.  On the other hand, 
highly purified or enriched PHFs seem to carry an assort- 
ment of antigenic  epitopes that were encountered  in other 
proteins like ubiquitin (43, 48, 56), tau (18, 35, 44, 56, 72), 
neurofilaments  (2,  10,  39,  41,  47)  and other microtubule- 
associated proteins  (34,  47).  The  purification  scheme de- 
scribed here permitted the conservation of some of these epi- 
topes, which suggests they may be "intrinsic" components of 
AD-PHF. Moreover, to the best of our knowledge, antibodies 
raised  against  either  PHF  or  APCP  do  not  show  cross- 
reactivity (54).  This also suggests nonidentity between the 
two types of filaments. 
The  results  of  the  chemical  depolymerization  studies 
showed that lipofuscin granules seem to be chemically stable 
on brief exposure to concentrated formic acid and, therefore, 
can be eliminated by centrifugation.  By contrast,  PHF and 
APCP are apparently depolymerized by formic acid and are 
probably disrupted to random coils. Upon removal of formic 
acid by dialysis against 6  M  GHC1, PHF polypeptides re- 
mained in solution whereas APCP repolymerized. It could 
be argued that the very hydrophobic nature of the APCP in- 
duces the regeneration of its supromolecular structure, even 
in the presence of a hydrophilic strong electrolyte. This im- 
portant thermodynamic behavior suggests major physicochemi- 
cal differences between the structures of APCP and PHF. 
Similarly, the amino acid composition of the APCP and 
PHF proteins obtained after fractionation by size exclusion 
chromatography demonstrate significant differences. In sup- 
port  of these  compositional  deviations,  which  have been 
highlighted  in  Results,  are  the  stoichiometric  differences 
within and between the fractions separated by the two chro- 
matographic steps. The most representative APCP fraction 
is fraction 4, accounting for 57 % of the entire sample, with 
an  apparent  Mr  of ~5,000.  With  some  minor deviations, 
this peak closely corresponds to the 13-amyloid protein. On 
the other hand, the most representative fraction in the PHF 
preparation, with an estimated 64% of the total sample, ap- 
pears after the  1,700-Mr  marker. Either this peptide has an 
anomalous retention time in the TSK 3000 SW column (Beck- 
man Instruments,  Inc.,  Altex Division) or this  fraction is 
Figure 5.  Higher magnification electron micrograph of a PHF cytoskeleton showing a homogeneous composition.  The outlined area (A) 
has been enlarged in the bottom panel (B). PHF appear in a random array as unbranched filaments with well-defined profiles and with 
no other discernable structures in the background. Their apparent straight rigidity may be the result of their helical configuration in contrast 
to the very flexible "monofilamentous" structures of APCP. On methodic and careful screening of PHF cytoskeletons at high magnification, 
no filaments other than PHF were observed.  Bars:  (A) 3 tim;  (B) 0.5  ~tm. 
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APCP, and Lipofuscin* 
Amino 
acid  PHFs¢  APCPJ;  Lipofuscin 
(mol/lO0 residues)  (mol/lO0  residues)  (mol/lO0  residues) 
Cys  ND  0.8§  16.3§ 
Asp  9.0  8.1§  8.2§ 
Met  1.1  2.7  1.5 
Thrll  5.0  1.4  4.1 
Serll  8.8  4.8  6.4 
Glu  10.7  9.6  7.8 
Pro  4.0  1.1  2.7 
Gly  12.7  15.5  12.5 
Ala  5.1  8.8  6.3 
Vall  8.8  14.3  8.1 
llel  5.2  6.5  4.3 
Leu  6.6  6.1  7.7 
Tyr  2.6  1.7  2.3 
Phe  3.3  6.3  5.1 
His  3.5  5.0  0.9 
Lys  9.3  5.2  3.3 
Arg  4.3  2.1  2.5 
Trp  ND  ND  ND 
* Average values from determinations at 24, 48, and 72 h of hydrolysis,  ex- 
cept as noted. 
Highly significant  differences between PHF and APCP; Chi-square =  33.780, 
P  =  0.002. 
§ Quantitated as cystic  acid and methionine sulfone after performic acid oxi- 
dation. 
II Extrapolated to 0  h hydrolysis value. 
¶ 72 h hydrolysis value. 
composed of 2-3 peptides of similar size. If the former alter- 
native applies, one could assume a peptide with a minimum 
length of 31-33 amino acid residues, as calculated from the 
peak's amino acid analysis molar ratios.  Next in representa- 
tion is the PHF fraction  1 (18%).  This peak,  which elutes 
with an Mr of ",~ 200,000, resembles fraction 4 in amino acid 
composition. Therefore, the possibility of this being an ag- 
gregated  form of the major fraction 4 exists. However, frac- 
tion  1 is the only  one in the entire  set of TSK  3000  SW- 
separated  peptides  that  is  immunochemically  positive  for 
ubiquitin,  tau,  and neurofilament  epitopes.  Last is the high 
degree of similarity that exists among PHF fractions 2,  3, 
and 5,  with peak 5,  again,  possibly  representing  an anom- 
alously  retained  peptide. 
Of particular  interest  was the  proteolytic  signal  protein 
ubiquitin  (76 amino acids long), which appeared  to be inti- 
mately associated and perhaps covalently linked to the PHF 
polypeptides,  since it continued to be present even after the 
repolymerization procedure.  Mori et al.  (43)  have  isolated 
from PHF preparations  peptides that correspond to two in- 
ternal  sequences of ubiquitin. 
The primary  goal in devising a technique that would per- 
mit large-scale purification of brain cells from suitable  AD 
postmortem material  was that,  in the absence of an animal 
Figure 7. Immunochemical  reactivity of PHF cytoskeletons derived 
from  the  2.0/1.7-M  sucrose  interface,  stained  by  indirect  immu- 
nofluorescence  with FITC-conjugated  second  antibody.  (A)  Anti- 
ubiquitin; (B) antitau; (C) antineurofi|ament (8D8 antibody). Bars, 
30  gm. 
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Paired Helical Filament Proteins 
Size exclusion HPLC on a TSK 3000 SW column 
Peak  I  Peak 2  Peak 3  Peak 4  Peak 5 
Mr 200,000  Mr 9000  Mr 4500  Mr --  Mr -- 
mol%  mol  %  mol%  mol  %  mol% 
Cys  ND  ND  ND  ND  ND 
Asp  il.3  8.7  8.4  10.5  8.3 
Thr  4.2  3.1  3.6  3.1  3.7 
Ser  10.5  13.3  13.9  10.6  12.9 
Glu  21.0  17.2  17.6  24.3  17.2 
Pro  4.0  3.1  3.4  3.3  3.8 
Gly  15.5  22.0  21.6  16.1  20.4 
Ala  7.2  7.9  7.6  6.5  8.2 
Val  5.7  6.0  5.0  5.9  4.9 
M~  0.6  .... 
Ile  2.7  2.9  2.9  3.1  3.2 
~u  5.0  4.4  5.2  5.8  6.3 
Tyr  1.3  0.9  1.0  1.0  0.6 
Phe  1.9  2.7  2.7  2.6  2.3 
His  1.6  2.0  1.2  1.6  1.6 
Lys  4.7  3.0  3.1  3.1  3.5 
Arg  2.8  2.8  2.8  2.5  3.1 
T~  ND  ND  ND  ND  ND 
between  the disappearance  of microtubules  and  neurofila- 
ments and the appearance of PHF cytoskeletons, which ap- 
pear to carry epitopes of the former structures.  We believe 
that these two phenomena are related (16). Great emphasis 
has been put upon the characterization of PHF,  partly be- 
cause,  with the exception of those seen  in aging,  they are 
alien to the normal neuron and because they appear in such 
profusion. However, of equal importance is the question of 
Figure  8.  Electron  micrographs  of  stained  APCE  APCPs  are 
formed by the compact aggregation of filaments, measuring 10 nm 
in  diameter,  which  appear  flexible.  (A)  A  dense  amyloid  core  Cys 
purified by the present protocol. (B) After treatment with concen-  Asp 
trated formic acid for 2 h at room temperature, the specimen was  Thr 
diluted with 50 vol of water and lyophilized.  APCPs were resus-  Ser 
pended in 50 mM Tris-HC1, pH 7.5, 0.2% SDS. An aliquot of this  Glu 
specimen was sonicated and a drop was deposited onto a Formvar-  Pro 
coated copper grid.  After 3  min, excess buffer was drained away  Gly 
by filter paper.  The grid was washed three times with water and  Ala 
stained with 1% aqueous uranyl acetate for 4 min. The repolymer-  Val 
ized APCP appeared as a network of 10-nm filaments morpholog-  Met 
ically indistinguishable from those  shown at the periphery  in A.  lle 
Leu 






model,  access  to  pathological  neurons  would  allow  for  a 
more selective investigation of the cellular pathophysiology 
of AD at different stages of its evolution.  Of immediate par- 
ticular interest was the suggestion of a reciprocal relationship 
Table IV.  Amino Acid Composition  of Alzheimer's  Disease 
Amyloid Plaque Core Proteins 
Size exclusion HPLC on a Superose 12 column 
Peak  1  Peak 2  Peak 3  Peak 4  Peak 5 
Mr 200,000  Mr 33,000  M,  10,000  Mr 5,000  Mr -- 
mol%  mol%  ~1%  mol%  mol% 
ND  ND  ND  ND  ND 
8.7  9.6  8.2  8.1  8.0 
4.7  4.4  0.8  0.3  2.6 
8.1  6.8  5.2  4.8  6.7 
10.8  12.9  10.8  9.9  9.8 
4.6  3.9  0.7  0.2  4.5 
12.3  11.6  16.5  16.1  21.6 
7.9  9.4  9.3  9.1  9.5 
7.5  7.5  14.2  14.5  7.6 
2.3  2.0  2.1  2.7  1.8 
4.4  4.2  6.0  6.0  4.3 
8.0  8.7  5.8  5.7  5.3 
3.2  2.9  2.7  2.6  4.1 
3.7  3.8  5.9  6.8  3.5 
3.0  2.7  5.9  6.8  3.6 
4.4  4.1  3.7  4.5  2.5 
6.4  5.5  2.2  1.9  4.6 
ND  ND  ND  ND  ND 
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Figure 9. Chromatographic profiles of PHF and APCP peptides.  (A) 
Size exclusion chromatography of PHF on a TSK 3000 SW column 
(7.5  ×  600 mm; Beckman Instruments,  Altex Division)  equipped 
with a guard column (75  ×  7.5 mm; Altex Scientific Inc.) contain- 
ing the same bed material,  equilibrated  with 6 M GHCI containing 
5% formic acid. The chromatography was developed at a flow rate 
of 0.5  ml/min and monitored at 280 nm.  The column was cali- 
brated, using the same denaturing solvents as described above, with 
10 different  proteins  and peptides  of known Mr:  myosin, phos- 
phorylase B, BSA, ovalbumin, carbonic anhydrase, soybean trypsin 
inhibitor, hemoglobin I]-chain, insulin, glucagon, and neurotensin. 
300-~tl aliquots of solubilized  PHFs were centrifuged at 250,000 g 
for 20 min before loading onto the column. PHFs resolved into five 
different  peaks  with Mrs of "~ 200,000  (peak  1), 9,000  (peak  2), 
4,500 (peak  3); peaks 4 and 5 eluted  after the 1,700 marker.  The 
amino acid compositions of these fractions is shown in Table III. 
The yield in nmol for each of the fractions permitted the calculation 
of their relative fractional  representation  as 18, 4, 6, 64, and 8 %, 
respectively.  Immunodot blot analyses indicated that only the pro- 
tein eluted  in peak 1 contained ubiquitin,  tau,  and neurofilament 
epitopes.  (B) Size exclusion  chromatography of APCP on a Su- 
perose 12 column (10 × 300 mm; Pharmacia Fine Chemicals,  Pis- 
cataway, NJ) equilibrated  with 70% formic acid. The column was 
calibrated  with known standards  in 70% formic acid, as describe( 
above, with the exception that the hemoglobin I~-chain was replace~ 
by lysozyme. Before  loading,  the APCPs were  dialyzed again, 
70% formic acid, followed by centrifugation  at 250,000 g for 2 
min. Aliquots of 300 Ixl were loaded and the chromatography deve 
oped at a flow rate of 0.2 ml/min.  Each of the five fractions w~ 
represented  as follows: peak 1 =  Mr 200,000 (15%); peak 2  =/I 
33,000 (4%); peak 3 =  Mr 10,000 (22%); and peak 4  =  Mr 5,0( 
(57%).  Peak 5, with an undetermined Mr,  represented  only 29 
why some of the normal cytoskeletal components disappear. 
This severely compromises vital neuritic transport which, in 
the ultimate  instance,  terminates  the propagation of action 
potentials. 
It is noteworthy that the 13-amyloid protein obtained from 
the neuritic plaques of AD appear to be more insoluble than 
the I~-protein deposited around blood vessels in the amyloid 
angiopathy of AD. This latter protein can be isolated under 
milder conditions (13),  readily penetrates  acrylamide gels, 
and  is accessible to routine  reverse-phase chromatography 
(46). If both 13-proteins  have the same amino acid sequence, 
then posttranslational changes, such as the large amounts of 
racemized amino acids found in the APCP (55), may confer 
on this amyloid different conformational characteristics ren- 
dering it more insoluble and prone to aggregation. 
A  plausible  interpretation  of the  accumulation  of PHFs 
may have to do with their insolubility, x-ray diffraction anal- 
ysis of PHF supports this issue since their predominant mo- 
lecular structure is that of an antiparalle113-pleated sheet con- 
formation (32).  The most favored composition of residues 
between 13-sheet interfaces makes the contact surfaces very 
stable and hydrophobic, bringing their interactions close to 
the minimum free energy conformation (8). In addition, the 
in vitro resistance that PHF show to a wide variety of proteo- 
lytic enzymes supports this line of reasoning (51, 53). Partial 
enzymic hydrolysis seems to take place only after PHFs were 
subjected to the powerful denaturing action of concentrated 
formic acid (43). At this point, the suggestion could be made 
that PHF accumulation represents a failure in the ubiquitin- 
mediated proteolysis. This failure could occur as the result 
of steric hindrance. Alternatively, some hydrolysis could oc- 
cur but PHF degradation and dissociation might be inhibited 
because its tertiary and quaternary structures are thermody- 
namically very stable. 
The  techniques  and  information  advanced  in this  paper 
should directly provide a  better understanding  of this  fila- 
mentous pathology and may ultimately  furnish a view into 
the etiopathogenesis of the dementing process in Alzheimer's 
disease. 
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